Growing clinical trials and approvals to novel treatments are fueling the expansion of the global vitiligo treatment market

calendar_today 29 August, 2022 person_outline Growth Plus Reports

According to the deep-dive market assessment study conducted by Growth+ Reports, the Global vitiligo treatment market was pegged at ~US$ 1.42 billion in 2021. The market is expected to witness a CAGR of ~ 6.14 % from 2022 to 2030.

The primary drivers propelling the global vitiligo treatment market is the growing prevalence of vitiligo due to environmental and genetic factors, high exposure to sun and strong chemicals and increasing development of innovative drugs. However, concerns over the patent expiration of branded drugs and the high cost of vitiligo treatment are projected to impede market growth. 

Environmental and genetic factors are mainly contributing to the high prevalence of vitiligo. Environmental factors such as stress, sunburn, skin trauma and exposure to certain chemicals can result in leucoderma or vitiligo. Stress interferes with the hormonal balance, increasing the level of catecholamines, neuropeptides, and cortisol which is often higher in vitiligo patients. Another risk factor which increases the prevalence of vitiligo is excessive sun exposure or UV exposure. It increases the levels of free radicals in the body, which are unstable molecules and damage the skin. This imbalance causes oxidative pressure, leading to immune response against melanocytes. Additionally, according to the NCBI (National Center of Biotechnology Information) estimates, global prevalence of vitiligo ranges from 0.004% to 2.28% in 2021. Genetic factor is another leading cause of vitiligo. Chances of getting vitiligo is 5% or 5 times higher if a first-degree family member is affected by the condition. The variations in genes NLPR1 and PTPN22 are likely associated with developing vitiligo in genetic conditions. These differences in the proteins produced by NLPR1 and PTPN22 makes it more difficult for the body to control inflammations and prevent the immune system from attacking its own tissue. 

Many new innovative drugs are approved for the treatment of vitiligo. For instance, JAK inhibitors such as ruxolitnib and tofacitinib are used in vitiligo treatment. The mechanism of action includes downregulation of JAK-STAT pathway. This decreases interferon-gamma, which is associated with cell mediated immunity in vitiligo. Stem cells have the potential to be used as a targeted treatment for vitiligo due to their anti-inflammatory and immunomodulatory capabilities. Exosomes, which operates as effective medication carriers by delivering cargo to target cells, are accompanied by MSC-derived extracellular vesicles, a developing management strategy.

North America, European, Asia Pacific, and Rest of the World regions make up the global market for vitiligo treatments. On the global front, North America has dominated the vitiligo treatment market. High adult vitiligo prevalence, greater awareness, better reimbursements, and the presence of numerous market players are the factors contributing to the prominent position of North America market. Additionally, a survey found that vitiligo affects people in the range of 0.76% and 1.11%, or 1.9 million cases and 2.8 million cases in 2020. The Global Vitiligo Foundation based in United States provides full coverage for the treatment requirement. The program mainly focuses on the improvement of the quality of life for individuals with vitiligo through guidance, research, clinical care, and community support. Due to the presence of a huge patient population and a high number of clinical trials, Asia Pacific is expected to have significant growth throughout the projection period. Many drugs in this region are approved following clinical trials, which will eventually expand the global market.

Some of the prominent players operating in the global vitiligo treatment market are Incyte Corporation, Astellas Pharma Inc., Baxter International Inc., Dr. Reddy’s Laboratories Ltd., Pfizer Inc., Sanofi SA, Teva Pharmaceutical Industries, GlaxoSmithKline Plc, F. Hoffman La Roche AG, Eli Lilly and Company, Bausch Health Companies Inc., STRATA Skin Sciences, Dermavant Sciences, Inc., Aclaris Therapeutics Inc., Bristol - Myers Squibb, among others. 

This report entails a thorough quantitative analysis of the trends from 2022 to 2030 of the global vitiligo treatment market has been analyzed from three perspectives: treatment, disease type, and end user. Based on treatment the market is divided into topical treatment, surgical procedure, and light therapy. According to disease type it is classified into segmental vitiligo, and nonsegmental vitiligo. The end user segment is grouped into hospitals, and aesthetic clinics.  

awards awards key differentiators

Reach Us

Web –

// // // //